Table 2.
Patient Demographics and Clinical Characteristics
| |
Total participants |
|---|---|
| n=41 | |
| Mean (SD) age at Phase I baseline | 11.8 (2.8) |
| Sex (male) | 22 (54%) |
| Race | |
| Caucasian | 34 (83%) |
| African American | 5 (12%) |
| Caucasian/African American | 2 (5%) |
| Age of onset of bipolar disorder, years | 9.1 (3.3) |
| Mood state at Phase I study entry | |
| Manic | 18 (44%) |
| Mixed | 23 (56%) |
| Length of bipolar disorder illness, years at Phase I baseline | 2.3 (2.6) |
| Current psychiatric comorbid diagnoses | |
| Any ADHDa | 29 (71%) |
| Any DBDb | 11 (27%) |
| Any anxiety disorderc | 9 (22%) |
| Mean (SD) weight-adjusted total daily lithium dose at Phase II entry | 28.2 (6.7) mg/kg/day |
| Mean (SD) lithium concentration at Phase II entry | 1.1 (0.3) mEq/L |
| Mean length (weeks) of study participation in Phase II | 14.9 (3.0) |
a
ADHD, attention-deficit/hyperactivity disorder; ADHD-combined; ADHD-hyperactive/impulsive; ADHD-inattentive; ADHD-not otherwise specified.
b
DBD, disruptive behavior disorder; conduct disorder; oppositional defiant disorder.
c
Generalized anxiety disorder; panic disorder; posttraumatic stress disorder; social anxiety disorder; social phobia; specific phobia. Three patients met diagnostic criteria for more than one anxiety disorder.